Detailed Information

Cited 55 time in webofscience Cited 53 time in scopus
Metadata Downloads

Recent research trends and updates on nonalcoholic fatty liver diseaseopen access

Authors
Yoo, Jeong-JuKim, WonKim, Moon YoungJun, Dae WonKim, Sang GyuneYeon, Jong-EunLee, Jin WooCho, Yong KyunPark, Sang HoonSohn, Joo Hyun
Issue Date
Mar-2019
Publisher
KOREAN ASSOC STUDY LIVER
Keywords
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Clinical trial
Citation
CLINICAL AND MOLECULAR HEPATOLOGY, v.25, no.1, pp.1 - 11
Indexed
SCIE
SCOPUS
KCI
Journal Title
CLINICAL AND MOLECULAR HEPATOLOGY
Volume
25
Number
1
Start Page
1
End Page
11
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2337
DOI
10.3350/cmh.2018.0037
ISSN
2287-2728
Abstract
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yeon, Jong Eun photo

Yeon, Jong Eun
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE